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ABSTRACT 
Aims: The magnetic technique using a magnetic tracer and handheld magnetometer was successfully 
evaluated in breast surgery. Residual tracer at the injection site can cause susceptibility artefacts on 
breast magnetic resonance imaging (MRI), therefore for lesion localization a solid marker would be 
preferable. Four magnetic markers were developed for localization to evaluate its clinical applicability. 
Methods: Comparison was made of the maximum magnetic counts and artefact-volume on MRI.  
Results: All markers were successfully detected, the spring marker showed the highest mean magnetic 
counts (627.8±400.2, mean±SD) with unequal variances (p<0.001) and the butterfly marker showed the 
smallest mean artefact-volume (11.1±2.3 cm³) with a significant difference between markers (p=0.049).  
Conclusion: Localization using a magnetic marker is feasible and further evaluation is required within a 
clinical trial. 
HIGHLIGHTS 
 Magnetic markers developed for lesion localization were evaluated in a porcine model 
 Magnetic count and visibility on imaging modalities (MRI, US, etc.) were evaluated 
 The spring marker showed the highest mean magnetic counts (627.8±400.2, mean±SD) 
 The butterfly marker showed the smallest mean artefact-volume (11.1±2.3 cm³) 
 The magnetic markers were visible on ultrasound and mammography 
KEY WORDS 
Magnetic technique, magnetic markers, lesion localization, magnetometer, porcine model. 
ABBREVIATIONS 
BCS Breast conserving surgery 
MRI Magnetic resonance imaging 
SLNB Sentinel lymph node biopsy 
US Ultrasound 
WGL Wire guided localization 
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BACKGROUND 
In early stage breast cancer patients, breast conserving surgery (BCS) has been adopted as the standard 
treatment, replacing mastectomy for the majority of patients.(1, 2) Due to the wider use of breast 
cancer screening and advanced imaging modalities, breast cancer is diagnosed at an earlier stage. This 
has led to an increase in screen detected non-palpable tumours, resulting in an increase in patients 
eligible for BCS. In the United Kingdom, approximately 33% of all breast cancer cases are non-palpable. 
(3, 4) In addition, more patients are offered primary medical treatment further increasing the number of 
impalpable tumours and suitability for BCS. (5) The current standard technique for treatment of non-
palpable lesions is wire guided localized (WGL) excision. Drawbacks of WGL, include wire migration and 
unacceptable high re-excision rates which can exceed 20%. 4 These drawbacks have encouraged the 
development of novel techniques for lesion localization.  
One of these novel techniques is the magnetic technique which was first evaluated for sentinel lymph 
node biopsy (SLNB). The magnetic technique utilizes a handheld magnetometer to localize sentinel 
lymph nodes following a subcutaneous injection of super paramagnetic iron-oxide based magnetic 
tracer. Its non-inferiority to the standard for SLNB was first demonstrated in the SentiMAG Multicentre 
Trial (6) and these findings have now been confirmed by several other studies. (7-13) The first in women 
use of the magnetic technique for non-palpable lesion localization was performed in the MagSNOLL trial 
subsequent to successful implementation of the technique in porcine models. (4, 14) This trial showed a 
100% success rate in detecting the non-palpable lesions with a re-excision rate of only 10%, suggesting 
that the magnetic guidance may improve the quality of BCS by improving intra-operative guidance. 
A drawback of the magnetic technqiue for SLNB are susceptibility artefacts at the injection site seen on 
subsequent breast magnetic resonance imaging (MRI). (15) In a minority of patients who require breast 
MRI follow-up, this may negatively impact on the clinical value of breast MRI in view of data loss. 
However, the magnetic tracer is not visible on conventional imaging modalities (mammography and 
ultrasound (US)), or on histology. For lesion localisation a solid magnetic marker rather than a magnetic 
tracer would be preferrable, since a solid marker can be excised entirely and artefacts on subsequent 
MRI will be avoided. Four different magnetic markers were developed, to be injected into non-palpable 
lesions under US guidance and readily detectable with a handheld magnetometer. Since in certain 
clinical circumstances (e.g.: prior to primary medical therapy) magnetic markers are left in-vivo for a 
period of time and breast MRI is used to monitor response to treatment, we also evaluated artefacts 
resulting from these different solid magnetic markers. We evaluated the potential clinical applicability of 
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these magnetic markers within an in-vivo porcine model comparing detectability of the magnetic 
markers using a magnetometer, artefact volume on 1.5T MRI and visibility of the markers on other 
imaging modalities. 
 
METHODS 
The magnetic markers were evaluated in an in-vivo porcine model, which replicated the human size, 
vasculature and lymphatic drainage. This study was conducted at the IRCAD institute (Strasbourg, 
France) and at King’s College London (London, United Kingdom). Ethics approval was granted for animal 
experimentation by the IRCAD Ethics Review Board (Strasbourg, France; ref: 38.2011.01.008). All 
procedures performed during this study were in accordance with institutional guidelines.  
Magnetic markers 
Four ferromagnetic markers, made from stainless steel 430, each with a length of 4.5 mm and width of 
0.9 mm were developed and evaluated. The magnetic markers had the following shapes: (1) solid, (2) 
barrel, (3) spring and (4) butterfly and an amount of iron equivalent to 0.2, 0.05, 0.02 and 0.01 ml of 
magnetic tracer, respectively (Table 1).  
Magnetometer 
The handheld magnetometer used for the detection of the markers was developed by the University of 
Tokyo (Tokyo, Japan) and consists of a Hall effect sensor inside a permanent magnet. (16) The magnetic 
flux density measured by the magnetometer is displayed with a scale ranging from 0 to 999 magnetic 
counts; where a higher count is displayed when the magnetometer is in close proximity of a material 
with a strong magnetic field. An earlier prototype of this magnetometer was previously validated in a 
trial evaluating the magnetic technique of SLNB against blue dye as a standard. (9)  
The procedure  
Four mini-pigs were anesthetized and used to conduct the different in-vivo experiments. The magnetic 
markers were inserted into the target area using an 18 gauge spinal needle, consisting of an inner and 
outer needle. The inner needle was removed slightly and the magnetic marker was placed at the tip of 
the outer needle and sealed off with bone wax. Once the outer needle was injected into the target 
tissue, the magnetic markers were injected by pushing the inner needle back into the outer needle. Four 
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of the same magnetic markers were injected at a standardised distance subcutaneously into each of the 
mini-pigs, close to the nipples, with convenient distance between each injected magnetic marker (Figure 
1).  
Subsequently in-vivo measurements were performed and repeated three times with the handheld 
magnetometer. The tissues containing the magnetic markers were excised keeping a wide margin of 
tissue surrounding each magnetic marker. All tissues were marked and frozen overnight, in preparation 
for MRI assessment in the morning. 
All tissue materials were imaged using a 1.5T MRI scanner (Siemens MAGNETOM Aera) and a body coil. 
T1 TSE and T2* sequences were used with SE 2.5/3.25 mm; RT 300 ms; TE 11 (T1) and 6.15 (T2); 256x256 
pixels, FA 140 (T1) and 18 (T2); NA 1 (T1) and 2 (T2); echo train 3 (T1) and 1 (T2) (Figure 2). The markers 
were subsequently located with the handheld magnetometer and removed, apart from four – one of 
each subtype – which were fixed in formalin and preserved for further examination at King’s College 
London. After excision of the remaining magnetic markers, four pieces of tissue were scanned with MRI 
as a control to determine if there was any tissue artefact after removal of the magnetic markers. To 
evaluate the extent of the artefacts, a 3D model of the tissue and of the artefact was constructed using 
the MRI images (Figure 3). The volumes of the 3D artefacts were measured and compared. 
Segmentation, volume determination and evaluation of the artefacts was performed using MATLAB 
R2015a (MathWorks, United States), and Blender software (V2.76, Blender Foundation, The 
Netherlands). In addition, the preserved tissues were imaged whilst in their container using X-ray. The 
excised tissues were too small for US evaluation. Therefore, US assessment was undertaken by scanning 
fillets of chicken into which the magnetic markers were injected. 
Statistics 
The counts obtained for the different magnetic markers and the artefact volumes were statistically 
evaluated using analyses of variance after homogeneity between results was ruled out using Levene’s 
test. For equal variances a one-way ANOVA with Tukey HSD post-hoc test was performed and for 
unequal variances a Welch F-test with Games-Howall Post-hoc test. All statistical analyses were 
performed with IBM SPSS statistics 22 (SPSS Inc., Chicago, IL, USA). 
 
RESULTS 
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Magnetic marker detection 
A total of 16 magnetic markers were injected in four mini-pigs. All magnetic markers were successfully 
identified and descriptive statistics of the obtained magnetometer counts can be found in Table 2A. The 
mean highest magnetic counts were found with the spring (627.8±400.2) and the lowest with the 
butterfly marker (261.7±167.9). 
Levene’s test showed that the groups have unequal variances (p<0.001). The Welch F-test showed that 
the magnetometer counts are significantly different between groups (F (3,23.2) = 4.2, p=0.02). Using the 
post-hoc Games-Howell test, only one pair with significantly different mean counts was found; the 
butterfly and spring marker (p=0.05) with the spring having the higher magnetometer counts. All other 
pairs showed no significant difference between their mean counts (butterfly-barrel (p=0.08), solid-
butterfly (p=0.24), spring-barrel (p=0.46), solid-spring (p=0.90) and solid-barrel (p=0.94)).  
MRI artefact 
All artefacts caused by the magnetic markers were visible on T1 TSE and T2* scans and were heart 
shaped (Figure 2 and 3). Descriptive statistics of the MRI artefact volume measurements per marker can 
be found in Table 2B. The mean largest artefact volume was seen with the barrel (22.5±9.1 cm³) and the 
smallest with the butterfly marker (11.1±2.3 cm³). After excision of the magnetic markers, no magnetic 
artefacts were found on MRI with any of the magnetic markers. 
Levene’s test showed that the groups had equal variances (p=0.307). A one-way ANOVA showed that 
the volumes were different between groups (F (3, 12) = 3.5, p=0.049). However, Tukey’s HSD post hoc 
test showed no significantly different pairs (butterfly-barrel (p=0.06), butterfly-spring (p=0.08), solid-
butterfly (p=0.16), solid-barrel (p=0.93), solid-spring (p=0.96) and spring-barrel (p=0.99)). 
Other imaging modalities 
All magnetic markers were visible on X-ray and US (Figure 4). On X-ray the magnetic markers can be 
seen as an area of increased whiteness and on US the magnetic marker is visible as an area with 
increased echogenicity and a lack of echogenicity behind the magnetic marker. 
 
DISCUSSION 
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There are several commercially available markers for lesion localization but most markers are made 
from titanium, platinum or non-magnetic stainless steel and detected by either US or mammography 
but not by magnetometers, hence the need to develop magnetic markers. (17) One study evaluated the 
magnetic MaMaLoc marker in combination with a handheld magnetometer in 15 patients and reported 
an identification rate of 100%. (18) No re-excision rates were reported for this study. The magnetic 
markers developed and evaluated in this study were easily detectable with the handheld 
magnetometer, with high counts. The highest magnetometer counts were found with the spring 
markers and the lowest with the butterfly markers. A significant difference (p=0.05) was found between 
these two magnetic markers in terms of magnetometer counts. Furthermore, the spring, barrel and solid 
markers were easier to inject than the butterfly marker due to their barrel-like shape. With regards to 
the MRI artefact, the largest artefact volumes were observed with the barrel markers and the lowest 
with the butterfly markers. Statistically, there was no significant difference between the butterfly 
markers and the other magnetic markers. Migration of the markers could not be assessed, as movement 
of the markers could not be determined against a tumor center or other certain location. However, 
during excision of the markers, it was difficult to remove the marker within the tissue and precise 
excision guided by the magnetometer was required. Our team uses a disposable spinal needle and bone 
wax to inject the markers; this is a cheap and easy way of applying the technique compared to using 
inducers. The butterfly marker has the smallest artefact on MRI but low magnetometer counts which 
could render deep lesions challenging to detect. From a clinical perspective, the optimal magnetic 
marker is the solid marker since it has both a smaller artefact on MRI and has a higher magnetometer 
count. 
The feasibility of the magnetic technique was successful for lesion localization in patients with non-
palpable breast cancer within the MagSNOLL trial although this was using a different magnetometer 
(Sentimag, Endomagnetics, UK). Recent discovery of the post-operative MRI artefacts due to magnetic 
dye residue makes localization with a solid magnetic marker a more clinically attractive procedure. Post-
operative MRI is not an issue when the magnetic markers are used for pre-operative localization of 
impalpable tumors, as the magnetic marker will be excised during surgery and no artefact will remain. 
The magnetic markers were all visible both on X-ray imaging and under US, which ensures confirmation 
of correct placement and excision of the magnetic markers respectively under X-ray and US guidance. 
However, intra-operative US scanners might not have the same spatial resolution as those available at 
the radiology department and the magnetic marker might be more difficult to detect. In addition, as 
patients require subsequent SLNB, an additional tracer injection is necessary on the day of surgery. If 
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the MRI artefact due to residual magnetic tracer still poses a problem, SLNB can be performed using 
other tracers. (19-21)  
Patients requiring pre-operative MRI imaging, for instance patients undergoing primary chemotherapy, 
are eligible for localization using these magnetic markers but since the artefacts on MRI are large and 
will impact on the ability to report on response to treatment, the magnetic markers should be placed 
immediately prior to surgery, after completion of primary chemotherapy. It might also be possible to 
decrease the artefact, by making the magnetic markers thinner or by lowering the iron content of these 
magnetic markers. Furthermore, by using specific MRI sequences the MRI artefact might be sufficiently 
suppressed. (22, 23) 
For BCS, complete excision of the tumor is required and when this is not achieved, patients are offered 
additional surgery for re-excision. The MagSNOLL trial achieved a re-excision rate of just 10% suggesting 
that by improving localization using the magnetic technique, the precision of the BCS technique could 
also be improved. The magnetic counts provide the surgeon with a better sense of direction than with 
wire-guidance and the counts are proportional to the distance from the magnetic marker. Intra-
operative US has already been shown in a randomized controlled trial to reduce re-excision rates and 
this could be further improved for impalpable lesions by combining US with the magnetic markers. 
Other promising alternatives to WGL include radio-guided surgery – including radio-guided occult lesion 
localization, radioactive seed localization, and sentinel-node and occult-lesion localization. These have 
been shown to be effective for occult lesion localization, with high localization rates  (in the range of 
89.4 to 100%) and excellent surgical outcomes including a decrease in operation times, decrease in re-
operation rates, and lower margin involvement.(24) However, implementation as a standard has not yet 
been established as the oncological benefit has not been satisfactorily confirmed.(4, 25) Furthermore, 
use of radioactive therapies requires specialized logistics such as a nuclear medicine department and the 
centre needs to be in close proximity to the nuclear reactor due to short half-lives of the used 
nanocolloids. For radio-guided occult lesion localization and sentinel-node and occult-lesion localization 
the required maximum amount of time between operation and injection of tracers is 24 hours, which 
complicate the logistics in planning the surgery. This technique therefore still remains at specialized 
centres. (4, 24) 
Compared to radio-guided surgery and WGL, magnetic markers are not bound by limited time between 
injection and operation. The flexibility in operation planning logistics, the lengthy shelf life and ease of 
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use of the magnetic markers evaluated in this study highlight the need to evaluate these magnetic 
markers within a clinical trial in breast cancer patients. However, first further experiments are required 
to determine if these markers are safe to use by evaluating marker migration and leaching to 
surrounding tissues. Once markers are proven to be safe to use, a feasibility trial can be setup.  
 
CONCLUSION 
The magnetic technique using a magnetic marker and a magnetometer is feasible within in-vivo porcine 
experiments. The visibility under US and X-ray shows promise in the clinical use of the magnetic 
markers, however preoperative MRI imaging poses a challenge as artefacts due to the magnetic markers 
are too large for routine use prior to primary chemotherapy. Further clinical evaluation is needed 
preferably in a non-inferiority trial comparing against radio-guided occult lesion localization, and or 
WGL. 
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Table 1. Characteristics of ferromagnetic markers used during experiments. 
Table 2. Descriptive statistics of (A) magnetometer counts for each magnetic marker and (B) the 
magnetic resonance imaging (MRI) artefact volume measurements per marker. 
Figure 1. Injecting markers and excision of tissue: (A) injection of the magnetic markers into the tissue 
spinal needle delivery method, (B) identification of peak magnetometer counts at site of marker, (C) 
excision of tissue containing magnetic markers and (D) excised tissue prepared for magnetic resonance  
() imaging.  
 
Figure 2. Magnetic resonance imaging (MRI) of the markers in excised porcine tissue: (A) T1 MRI 
sequence, (B) T2 MRI sequence after excision of the markers (from left to right: solid – spring – butterfly 
– barrel),  (C) T1 MRI sequence showing an artefact (arrows) at the location of the butterfly markers and 
(D) T2 MRI sequence showing an artefact (A) at the location of the butterfly markers . 
 
Figure 3. T2 magnetic resonance imaging (MRI)  was used to segment a 3D image of the porcine tissue 
and artefacts caused by the butterfly markers with (A) T2 MRI image showing the artefact (A), (B) 3D 
segmented tissue (green) and artefact (blue), (C) segmented tissue and (D) segmented artefact.  
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Figure 4. Mammography (A) and ultrasound (B) images of solid markers in excised porcine tissue and 
chicken fillet. Mammography showing an area of increased density (arrow) and ultrasound showing an 
area of increased echogenicity (arrow) with a posterior acoustic shadow. 
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Table 1. Characteristics of ferromagnetic markers used during experiments. 
Name  Solid Barrel Spring Butterfly 
 
  
  
Length 4.5mm 4.5mm 4.5mm 4.5mm 
Diameter 0.9mm 0.9mm 0.9mm 0.9mm 
 
 
 
 
Table 2. Descriptive statistics of (A) magnetometer counts for each magnetic marker and (B) the MRI 
artefact volume measurements per marker. 
 N Mean Std. 
Deviation 
Std. Error 95% Confidence 
Interval for Mean 
Min Max 
Lower Upper 
A. Descriptive statistics of the obtained magnetometer counts per marker 
A Solid 12 514.3 411.6 118.9 252.7 775.8 35.0 999.0 
B Barrel 12 439.8 173.8 50.2 329.4 550.2 290.0 740.0 
C Butterfly 12 261.7 167.9 48.5 155.0 368.4 10.00 480.0 
D Spring 12 627.8 400.2 115.5 373.5 882.1 100.0 999.0 
Total 48 460.9 330.0 47.6 365.1 556.7 10.00 999.0 
B. Descriptive statistics of the MRI artefact volume measurements per marker 
A Solid 4 20.1 5.0 2.5 12.1 28.2 12.9 24.4 
B Barrel 4 22.5 9.1 4.5 8.1 37.0 11.6 33.7 
C Butterfly 4 11.1 2.3 1.1 7.5 14.8 9.3 14.5 
D Spring 4 22.0 3.8 1.9 16.0 27.9 17.8 27.0 
Total 16 18.9 6.9 1.7 15.3 22.6 9.3 33.7 
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 Magnetic markers developed for lesion localization were evaluated in a porcine model 
 Magnetic count and visibility on imaging modalities (MRI, US, etc.) were evaluated 
 The spring marker showed the highest mean magnetic counts (627.8±400.2, mean±SD) 
 The butterfly marker showed the smallest mean artefact-volume (11.1±2.3 cm³) 
 The magnetic markers were visible on ultrasound and mammography 
 
GRAPHICAL ABSTRACT 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
Four ferromagnetic markers were developed for lesion localisation and evaluated the potential clinical 
applicability of these markers within an in-vivo porcine model comparing (a) maximum magnetic counts, 
detected with a handheld magnetometer; (b) artefact volume on 1.5T MRI; and (c+d) visibility of the 
markers on other imaging modalities. This study showed that magnetic localisation using a 
ferromagnetic marker is feasible within an in-vivo porcine model and further evaluation is now required 
within a clinical trial. 
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